구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Leucovorin Calcium (Leucovorin Calcium) Ning Jin·Advanced Malignant Solid Neoplasm 154 trials·t½ 6.2 h |
|---|---|
Overview Program | Leucovorin Calcium |
Overview Company | Ning Jin |
Overview Modality | ANTIBODY |
Overview Target | Advanced Malignant Solid Neoplasm |
Overview Indication | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Biomarker | biomarker-selected immunochemotherapy and proposes a shift from dose-based to exposure-based paradigms |
PK/PD Half-life | 6.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pneumonitis: An Overlooked Complication |
Clinical Safety signal | Pneumonitis: An Overlooked Complication |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT00057811 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00057811 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Leucovorin Calcium (Leucovorin Calcium) Ning Jin·Advanced Malignant Solid Neoplasm 154 trials·t½ 6.2 h |
|---|---|
Overview Program | Leucovorin Calcium |
Overview Company | Ning Jin |
Overview Modality | ANTIBODY |
Overview Target | Advanced Malignant Solid Neoplasm |
Overview Indication | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Biomarker | biomarker-selected immunochemotherapy and proposes a shift from dose-based to exposure-based paradigms |
PK/PD Half-life | 6.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pneumonitis: An Overlooked Complication |
Clinical Safety signal | Pneumonitis: An Overlooked Complication |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT00057811 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00057811 |
추천 비교
추천 비교